5th International Conference on Heart and Cardiovascular Diseases

Hypertension affects 1.28 billion adults worldwide and remains the single largest modifiable cardiovascular risk factor, yet global blood pressure control rates remain below 25%. The Hypertension session examines the renal denervation resurgence following SPYRAL and RADIANCE sham-controlled trials, the new drug class of aldosterone synthase inhibitors (lorundrostat, baxdrostat) in resistant hypertension, zilebesiran, an RNA interference antihypertensive agent showing sustained BP reduction from twice-yearly dosing ambulatory BP monitoring in diagnosis, LVH regression strategies in hypertensive heart disease, and the distinct management challenges of hypertension in pregnancy and preeclampsia.

Scope of This Track

From blood pressure targets and combination pharmacotherapy to hypertension in special populations including resistant hypertension, hypertension in pregnancy, and renal considerations this track covers the full clinical spectrum.

Debates & Developments Driving the Field

• Optimal blood pressure targets — revisiting systolic thresholds in the light of SPRINT and STEP trial data
• Resistant hypertension — renal denervation, aldosterone antagonists, and newer agents
• Single-pill combinations — improving adherence and outcomes in routine practice
• Hypertension in chronic kidney disease — managing the cardiorenal continuum
• Hypertension in pregnancy — preeclampsia risk, treatment safety, and long-term cardiovascular sequelae

Clinical Focus Areas

• General & Clinical Cardiology Practice
• Blood Pressure Management & Monitoring
• Hypertension Diagnosis & Classification
• Guideline-Directed Hypertension Management
• Hypertension with Comorbid Conditions
• Patient Adherence & Long-Term BP Control
• Clinical Case Studies & Practice-Based Research
• Internal Medicine & Multisystem Cardiovascular Care
• Emergency & Acute Cardiovascular Care
• Case Reports & Challenging Clinical Cases
• Cardiac Nursing & Patient-Centered Care
• Cardio-renal Medicine
• Cardio-Oncology

Who This Track Is Built For

General Cardiologists, Hypertension Specialists, Nephrologists, General Physicians, Obstetricians with a cardiovascular interest, and Primary Care Physicians managing chronic cardiovascular risk.

What Delegates Take Back

• Clarity on evolving blood pressure targets across different patient risk profiles
• Evidence-based approaches to resistant and difficult-to-treat hypertension
• Strategies for improving adherence and long-term control in clinical practice
• Guidance on managing hypertension in high-risk and special populations

Bring Your Clinical Research: Researchers can submit clinical studies, hypertension trials, observational research, cardiovascular risk studies, therapeutic investigations, patient-outcome research, case reports, and innovative approaches to cardiovascular care. Submit Your Abstract →

Related Topics: Cardiorenal Medicine | Preventive Cardiology | Cardiometabolic & Lipidology | Coronary & Ischemic Heart Disease